Table 3. Mesenchymal markers examined by FACS.
Marker | Population | Phase A | Phase B | Phase C |
---|---|---|---|---|
CD29 | hMSC-20176 | 98% | 98% | 96% |
hMSC-21558 | 99% | 98% | 69% | |
Average | 98.5% | 98% | 83% | |
CD44 | hMSC-20176 | 99% | 99% | 95% |
hMSC-21558 | 99% | 98% | 75% | |
Average | 99% | 98.5% | 85% | |
CD45 | hMSC-20176 | 91% | 93% | 88% |
hMSC-21558 | 98% | 97% | 64% | |
Average | 95% | 95% | 76% |